Upgrade to SI Premium - Free Trial

Savara (SVRA)

5.51 -0.24 (4.17%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 4 Savara Inc For: Jul 15 Filed by: Lutz Robert Matthew July 24, 2026 6:25 PM - SEC Filing Palvella Therapeutics adds Matt Pauls to its board of directors June 30, 2026 7:30 AM - StreetInsider Form 4 Savara Inc For: Jun 22 Filed by: Lowrance David L June 22, 2026 8:18 PM - SEC Filing Form 144 Savara Inc Filed by: Lowrance David L June 22, 2026 3:09 PM - SEC Filing Savara Announces New Employment Inducement Grant June 12, 2026 4:05 PM - BizWire Form 8-K Savara Inc For: Jun 04 June 8, 2026 4:16 PM - SEC Filing Savara names Robert Lutz as chief operating and financial officer June 8, 2026 4:05 PM - StreetInsider Savara Announces Chief Financial and Administrative Officer Transition June 8, 2026 4:05 PM - BizWire Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference May 27, 2026 4:05 PM - BizWire Savara presents biomarker data from phase 3 trial at ATS conference May 20, 2026 8:15 AM - StreetInsider Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor May 20, 2026 8:15 AM - BizWire Savara presents long-term data from molgramostim trial extension May 19, 2026 2:15 PM - StreetInsider Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonar May 19, 2026 2:15 PM - BizWire Savara reports improved exercise capacity in aPAP drug trial May 18, 2026 2:55 PM - StreetInsider Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) May 18, 2026 2:55 PM - BizWire Savara (SVRA) Misses Q1 EPS by 3c May 12, 2026 5:06 PM - StreetInsider Form 10-Q Savara Inc For: Mar 31 May 12, 2026 4:06 PM - SEC Filing Savara Reports First Quarter Financial Results and Provides Business Update May 12, 2026 4:05 PM - BizWire Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference May 11, 2026 4:05 PM - BizWire Full Article List